share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q:季报延迟披露公告
美股SEC公告 ·  2024/08/14 19:14

牛牛AI助手已提取核心信息

bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
bluebird bio公司已向证券交易委员会(SEC)提交晚报告通知,表明该公司将无法在2024年8月14日的规定期限内提交截至2024年6月30日的第十号表格季度报告。延迟归因于该公司正在进行的重新编制其截至2022年12月31日和2022、2023年前三个季度的财务报表的工作。此重新编制过程还影响了其2023年年度报告和2024年第一季度报告的及时提交。bluebird bio正在努力完成重新编制工作,并尽快提交所有未完成的报告。公司预计,由于与合同制造组织的协议中的租赁和非租赁组件会计存在的已确定的错误,其2024年6月30日季度业绩与2023年同期相比将发生显着变化。但是,公司已经表示这些错误不会影响其现金头寸或营业收入。
bluebird bio公司已向证券交易委员会(SEC)提交晚报告通知,表明该公司将无法在2024年8月14日的规定期限内提交截至2024年6月30日的第十号表格季度报告。延迟归因于该公司正在进行的重新编制其截至2022年12月31日和2022、2023年前三个季度的财务报表的工作。此重新编制过程还影响了其2023年年度报告和2024年第一季度报告的及时提交。bluebird bio正在努力完成重新编制工作,并尽快提交所有未完成的报告。公司预计,由于与合同制造组织的协议中的租赁和非租赁组件会计存在的已确定的错误,其2024年6月30日季度业绩与2023年同期相比将发生显着变化。但是,公司已经表示这些错误不会影响其现金头寸或营业收入。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。